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Sir,
Elevated expression of carcinoembryonic antigen (CEA; CD66e;
CEACAM5) has been implicated in various biological aspects of
neoplasia. Carcinoembryonic antigen has been shown to be involved
in both homophilic and heterophilic binding (Benchimol et al, 1989),
suggesting to some that it is an intercellular adhesion molecule
involved in cancer invasion, adhesion, and metastasis (Yoshioka et al,
1998). Carcinoembryonic antigen also serves an anti-apoptotic
function (Ordonez et al, 2000). Studies have shown that CEA affects
the expression of various groups of cancer-related genes, especially
cell cycle and apoptotic genes, protecting colonic tumour cells from
various apoptotic stimuli, including 5-FU therapy (Soeth et al, 2001).
Conaghan et al, in the March issue of British Journal of Cancer,
described in vitro studies with a humanised anti-CEA antibody
(PR1A3), demonstrating its ability to react with a panel of CEA-
expressing colorectal cancer cell lines and induce ADCC activity.
The authors state that ‘there are so far no unconjugated, or ‘naked’
antibodies to CEA being used for treatment of colorectal cancer’
(Conaghan et al, 2008). Since this is not correct, we offer this
clarification. Dr Conaghan appears to be unaware of our work in
the field of anti-CEA therapy with the MN-14 (labetuzumab)
antibody. We have been studying the humanised anti-CEA
monoclonal antibody (MAb), hMN-14 or labetuzimab, both
prelinically and in patients, for a number of years. This MAb
binds with high affinity to the restricted A3B3 domain (Gold
group 3) found on CEA (Sharkey et al, 1995). Clinically, the MN-14
antibody was shown to have excellent targeting properties and the
potential for reduced immunogenicity (Sharkey et al, 1995), and
has been studied as a naked MAb in colorectal and breast
cancer patients (Immunomedics Inc., unpublished results), as well
as a radioconjugate (Hajjar et al, 2002; Liersch et al, 2005). The
technology to produce large quantities of recombinant humanised
MN-14 antibody in a bioreactor has been described (Qu et al,
2005). Furthermore, chimeric human T cells have been created that
express humanised MN-14 Fab, and MN-14 scFv joined to
immunoglobulin–T-cell receptors. These ‘designer T cells’
effectively kill CEA-expressing cancer cells, even in the presence
of high level of soluble CEA (Nolan et al, 1999).
Labetuzumab, as an IgG1 MAb, induces effector-cell function
(ADCC) in vitro against CEA-positive human colonic tumour
cells (Blumenthal et al, 2005b). Antibody targeting of CEA may also
modulate migration, invasion, and adhesion of human cancer cells
in vitro (Blumenthal et al, 2005a). Labetuzumab is able to inhibit
the growth of lung metastasis from colorectal cancer cells
expressing high levels of CEA or from colorectal cancer cells with
the lower expression of CEA, but in mice where levels of peripheral
WBCs were elevated by G-CSF (Blumenthal et al, 2005b). The MAb
also shows chemosensitising properties in both s.c. and metastatic
human colonic tumour cells propagated in nude mice. Adminis-
tration of labetuzumab enhanced the therapeutic effects of 5-FU
and CPT-11, two cytotoxic drugs frequently used in colorectal
cancer therapy (Blumenthal et al, 2005b). In another high CEA-
expressing human medullary thyroid cancer xenograft (TT), we
have shown that hMN-14 anti-CEA IgG can inhibit tumour cell
growth and also augment the effects of dacarbazine, which is active
in this cancer type (Stein and Goldenberg, 2004).
Although the PR1A3 antibody described by Conaghan et al in
March 2008 demonstrates some promising in vitro activity,
the experience with such humanised anti-CEA MAbs goes well
beyond these observations, as described by our own in vitro and
preclinical studies demonstrating direct, specific, anti-tumour
effects without conjugation to a cytotoxic agent, in both colorectal
and medullary thryroid cancer xenografts, providing evidence for
the superiority of the combined modality naked anti-CEA MAb
immunotherapy and chemotherapy treatments. The results sup-
port further studies focused on the integration of anti-CEA MAb
therapy into chemotherapeutic regimens for the improved
management CEA-expressing neoplasms.
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